TC
MRNS

TFS Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

TFS Capital’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,537
Closed -$78K – 1118
2015
Q4 		$78K Sell
2,537
-3,598
-59% -$106K 0.01% 680
2015
Q3 		$205K Buy
6,135
+1,728
+39% +$97.5K 0.02% 735
2015
Q2 		$204K Buy
+4,407
New +$165K 0.02% 745

Other funds holding MRNS

CPV
Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TFS Capital's MRNS Position: Q1 2016 in Review

TFS Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2016, closing a stake of 2,537 shares — an estimated $78K sold.

TFS Capital first reported a position in MRNS in Q2 2015 and held it in 3 quarters. The position peaked at $205K in Q3 2015. 31 funds tracked by Wall St. Rank hold MRNS as of Q1 2016.

  • TFS Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2016 after selling out during the quarter.
  • TFS Capital sold 2,537 Marinus Pharmaceuticals, Inc shares in Q1 2016, an estimated $78K.
  • TFS Capital first reported a position in Marinus Pharmaceuticals, Inc in Q2 2015 and held it in 3 quarters.
  • TFS Capital's Marinus Pharmaceuticals, Inc position peaked at $205K in Q3 2015.
  • 31 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2016.

Based on TFS Capital's 13F filing for Q1 2016, filed 10 May 2016.